Direxion Daily S&P Biotech Bear 3X Shares (LABD)

This instrument is a high-risk leveraged inverse ETF designed to profit from a collapsing biotech sector, yet the underlying asset class has shown remarkable resilience recently. The data reveals a catastrophic long-term trajectory: the price has lost 99.87% of its value over the last nine years, with every single year being negative. This is not a temporary dip; it is a structural implosion where the market has repeatedly punished the asset, leaving it at a fraction of its historical value. Despite this, the fund pays a 6.96% dividend, which is a dangerous signal for a leveraged product—it indicates the fund manager is selling the underlying assets to cover payouts, accelerating the erosion of the remaining principal. Short-term momentum is weak, with the price trading significantly below its 50-day and 200-day averages, and the statistical forecast offers no directional clarity. The options market confirms this pessimism, with traders placing heavy bets on further declines. For a long-term investor, this is a value trap; the low price reflects the reality that the business quality driving the index has deteriorated so severely that even a 99% drop hasn't made it cheap. The dividend is a tax on the remaining capital. Avoid.